Sanofi: heads the CAC, thanks to UBS comments
(CercleFinance.com) - On Wednesday the Sanofi share leads the CAC 40, with UBS analysts upgrading it to buy.
Its share is currently up 2% at 76.9 euros, while the CAC is down 0.7%.
"The current share price implies, with consumer health on a peer multiple, the pharma and vaccines businesses are being assigned 9.8x 2020 PE for c.3% 19-23 CAGR," UBS says.
UBS has therefore upgraded its rating on the share from "neutral" to "buy," while raising its corresponding target price from 79 euros to 87 euros.
Copyright (c) 2019 CercleFinance.com. All rights reserved.
The information and analyses distributed by Cercle Finance are only intended as decision-making support for investors. Cercle Finance's responsibility may not be entailed, either directly or indirectly following the use of such information and analyses by readers. Any non-professional investor is recommended to consult a professional advisor before making any investment decision. This indicative information in no way constitutes any invitation to sell or buy securities.
Its share is currently up 2% at 76.9 euros, while the CAC is down 0.7%.
"The current share price implies, with consumer health on a peer multiple, the pharma and vaccines businesses are being assigned 9.8x 2020 PE for c.3% 19-23 CAGR," UBS says.
UBS has therefore upgraded its rating on the share from "neutral" to "buy," while raising its corresponding target price from 79 euros to 87 euros.
Copyright (c) 2019 CercleFinance.com. All rights reserved.
The information and analyses distributed by Cercle Finance are only intended as decision-making support for investors. Cercle Finance's responsibility may not be entailed, either directly or indirectly following the use of such information and analyses by readers. Any non-professional investor is recommended to consult a professional advisor before making any investment decision. This indicative information in no way constitutes any invitation to sell or buy securities.